Molecular Partners has announced that it is collaborating with Novartis on potential medicines for use against COVID-19. Molecular Partners will be responsible for Phase 1 and 2 trials for its two therapeutic candidates. If the trials are successful, Novartis will be responsible for further development, manufacturing, and global commercialization.
Molecular Partners will commence Phase 1 and Phase 2 trials of its DARPin therapeutics in November 2020. If the trials are successful, the candidates could receive emergency use approval. Should Novartis exercise its option, it would be responsible for further development, manufacturing, distribution, and commercialization.
DARPin therapeutics are a new class of custom-built protein therapeutics based on natural binding proteins. As Molecular Partners explains, these have several characteristics that make them ideally suited for antiviral therapy.
Read more about this promising collaboration in the article by Greater Zurich Area.